Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MKNK1 | Q9BUB5 | 4/20 | 0.74 |
| ▸ | MKNK2 | Q9HBH9 | 4/20 | 0.74 |
| ▸ | DRD4 | P21917 | 10/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | DRD2 | P14416 | 9/20 | 0.64 |
| ▸ | DRD3 | P35462 | 8/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19805568 | 0.91 | DRD4 (0.76) | MKNK1MKNK2DRD4KMT2AMEN1 | |
| SCHEMBL10070042 | 0.84 | MKNK1 (0.75) | MKNK1MKNK2DRD4KMT2AMEN1 | |
| SCHEMBL20939706 | 0.83 | MKNK1 (1.00) | MKNK1MKNK2DRD4KMT2AMEN1 | |
| Hydrochloric Acid SCHEMBL19410715 | 0.82 | MKNK1 (0.97) | MKNK1MKNK2DRD4KMT2AMEN1 | |
| SCHEMBL22555697 | 0.82 | USP30 (0.60) | MKNK1MKNK2DRD4KMT2AMEN1 | |
| SCHEMBL15074625 | 0.78 | MKNK1 (0.64) | MKNK1MKNK2DRD4KMT2AMEN1 | |
| SCHEMBL14686771 | 0.77 | DRD4 (0.69) | DRD4DRD2DRD3POLBS1PR2 | |
| SCHEMBL2755249 | 0.76 | MKNK1 (0.49) | MKNK1MKNK2DRD4KMT2AMEN1 | |
| SCHEMBL5765218 | 0.75 | MKNK1 (0.70) | MKNK1MKNK2DRD4KMT2AMEN1 | |
| SCHEMBL25431152 | 0.74 | MKNK1 (0.59) | MKNK1MKNK2DRD4KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210254056-A1 | IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS | CAMP4 THERAPEUTICS CORPORATION | 2021-08-19 | — | — | US | disclosed |
| EP-2568812-B1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-10-26 | — | — | EP | disclosed |
| EP-2568812-B1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-10-26 | — | — | EP | disclosed |
| US-9365539-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365539-B2 | Prolylcarboxypeptidase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-06-14 | — | — | US | disclosed |
| CN-101812054-B | 1-acetyl-N-phenyl-N-(3-(4-(3-phenyl-1-H-pyrazole-5-radial)piperidine-1-radical)propyl)-4-amide derivative and preparation method thereof | UNIV BEIJING TECHNOLOGY | 2014-01-22 | — | — | CN | disclosed |
| EP-2568812-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2013-03-20 | — | — | EP | disclosed |
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-14 | — | — | US | disclosed |
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-02-14 | — | — | US | disclosed |
| WO-2011143057-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-11-17 | — | — | WO | disclosed |
| WO-2011143057-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-11-17 | — | — | WO | disclosed |
| CN-101812054-A | 1-acetyl-N-phenyl-N-(3-(4-(3-phenyl-1-H-pyrazole-5-radial)piperidine-1-radical)propyl)-4-amide derivative and preparation method thereof | UNIV BEIJING TECHNOLOGY | 2010-08-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130040929-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | PRCP, PREP, ENPEP | MKNK1 1365/4885MKNK2 2027/4885DRD4 4740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.